Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: Do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up

Debabrata Mukherjee, Eric J. Topol, Michel E. Bertrand, Steen D. Kristensen, Howard C. Herrmann, Franz Josef Neumann, Steven J. Yakubov, Jean Pierre Bassand, Rick R. McClure, Gregg W. Stone, Diego Ardissino, David J. Moliterno

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Aims: Compared with placebo, abciximab has been associated with mortality reduction at late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab provide similar efficacy outcomes among patients undergoing non-emergent, stent-based percutaneous coronary intervention. We report here the 1-year mortality of the study population. Methods and results: In 18 countries at 149 hospitals, 4809 patients undergoing elective or urgent stent implantation were randomly assigned a bolus and infusion of tirofiban or abciximab. Ischaemic events were assessed at 30 days and 6 months and mortality was assessed at 1 year. We previously reported that abciximab was superior to tirofiban considering the composite rate of death or myocardial infarction at 30 days among all patients and at 6 months among those with an acute coronary syndrome (ACS). At 1-year follow-up death occurred in 46 (1.9%) patients who received tirofiban and 42 (1.7%) patients who received abciximab (hazard ratio 1.10, 95% CI 0.72-1.67; P=0.660). Mortality rates for patients with ACS were 2.3% with tirofiban vs. 2.2% with abciximab (hazard ratio 1.03, 95% CI 0.64-1.67; P=0.897) and those without ACS were 1.4 vs. 1.0% (hazard ratio 1.32, 95% CI 0.56-3.13; P=0.530). Conclusion: At 1 year, tirofiban provided a similar level of survival benefit compared with abciximab.

Original languageEnglish
Pages (from-to)2524-2528
Number of pages5
JournalEuropean Heart Journal
Volume26
Issue number23
DOIs
StatePublished - Dec 2005

Bibliographical note

Funding Information:
Conflict of interest: Dr Howard C. Herrmann is a consultant to Millenium Pharmaceutical Inc., has received honoraria for speaking from Johnson and Johnson, and received research funding from Millenium, Johnson and Johnson, Merck, and Guilford Pharmaceuticals. Dr Rick McClure is a medical advisor for the Medicines Company. Dr David Moliterno has received research funding from Guilford Pharmaceuticals. Dr Diego Ardissino has received research grants and honorarium from Eli Lilly, Merck, and Schering Plough. None of the other authors have any potential conflict of interest.

Keywords

  • Abciximab
  • Glycoprotein IIb/IIIa inhibitor
  • Mortality
  • Percutaneous coronary intervention
  • Tirofiban

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: Do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up'. Together they form a unique fingerprint.

Cite this